News

Our Chief Scientific Officer, Asger Bihlet, will be a speaker on the OARSI Live Webinar on Phenotyping. The webinar is entitled: “Challenges and Opportunities of Phenotyping in Osteoarthritis”, and will be held Wednesday, January 18, 2023, 8:00-9:00 am EST.

NBCD will be participating in the virtual part of JPM 2023, represented by Chief Commercial Officer, Casper Clemmensen, who will be sharing our unique expertise and insights on OA.

The new office environment supports our close collaboration across the teams and offers a range of meeting rooms, areas for shorter informal meetings, soft seating, a quiet zone, and a shared café/canteen – all in modern décor with plenty of colors.

The paper is entitled “Impact of Monitoring Approaches on Data Quality in Clinical Trials - A Cross-Study Comparison of Risk-Based Monitoring and Classic Monitoring”, and is authored by: Jeppe Ragnar Andersen, Christoffer von Sehested, Inger Byrjalsen, Sara Popik, Anne Bo Follin, and Asger Bihlet.

For the third year in a row, NBCD is the proud receiver of the Danish Business Award: A Børsens Gazelle. In 2022, we have welcomed 14 new team members in Denmark alone and we look forward to expanding even further in 2023.

The NBCD science-team will be present at this year's American College of Rheumatology Convergence on 11-14 November in Philadelphia, USA. Here, they will present the Ignite poster: “Antihistamine Use and Structural Progression of Knee OA: A Post-Hoc Analysis of Two Phase 3 Clinical Trials”.

CCO, Casper Clemmensen, is attending BIO-Europe 2022 in Leipzig these days. With a packed calendar, he is ready to discuss assets within musculoskeletal indications and help drive the development of this important area.

The paper is entitled: "Effect of adrenaline on serum mid-regional pro-atrial natriuretic peptide and central blood volume" and is based on a subgroup of patients from the EFEX-OA-02 study, registered at clinicaltrials.org (registration no. NCT04542668)

The paper is entitled: "An estimate of plasma volume changes following moderate-high intensity running and cycling exercise and adrenaline infusion" and is based on the EFEX-OA-02 trial done in a wide collaboration between NBCD, Sanos Clinic, Rigshospitalet, Nordic Bioscience A/S and KU.

The dedicated science-team from NBCD is attending EULAR these days with a poster, a poster-tour, a publication, and an oral presentation. Our CSO, Asger Bihlet, will be presenting our most recent data, suggesting a role of mast cell inhibition in the treatment of OA, based on data from a large osteoarthritis cohort on June 3rd in Auditorium 15